Abstract: FR-PO1089
Degree and Prediction of Response to Intradialytic Parenteral Nutrition Therapy in a Large Cohort of Malnourished Patients on In-Center Hemodialysis: A Retrospective Analysis
Session Information
- Health Maintenance, Nutrition, and Metabolism
November 07, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Health Maintenance, Nutrition, and Metabolism
- 1500 Health Maintenance, Nutrition, and Metabolism
Authors
- Slusser, Maiya, Patient Care America, Pompano Beach, Florida, United States
- Haight, Jamie, Patient Care America, Pompano Beach, Florida, United States
- Hardy, Mark A, Columbia University, New York, New York, United States
- Hehenberger, Karin, Patient Care America, Pompano Beach, Florida, United States
Background
Serum albumin (Alb) strongly predicts mortality and morbidity of in-center hemodialysis (ICHD) patients, increasing Alb has been shown to improve patient outcomes. Our study of 1631 ICHD patients on intradialytic parenteral nutrition (IDPN) showed efficacy and safety in a diverse patient population. Here we evaluate a subset of that cohort to categorize degree of response.
Methods
452 adult ICHD patients with 3-mo avg baseline Alb <3.5g/dL initiating IDPN in 2021 were followed through the first 6mos. of therapy. Patients were sorted into 1 of 3 groups based on Alb at 6mos.: Gr1, Alb decreased from baseline; Gr2, Alb stabilized at 0.0g/dl to <0.3g/dL; Gr3, Alb increased ≥0.3g/dL. Baseline variables were compared using 1-way ANOVA for continuous variables and chi-square for categorical.
Results
84% of patients responded to therapy, 61% showed an increase of ≥0.3g/dL. Lower baseline Alb results in greater Alb improvement. Peak Alb, the highest Alb reached within 6mos of therapy, was reached most often in month 6 in Gr 3 with an avg of 4.3mos. While Gr1 and Gr2 peaked in mos. 1 and 2 respectively. The avg change between baseline and peak Alb in Gr1, Gr2, and Gr3 were 0.11g/dl, 0.34g/dL, and 0.72g/dL respectively. The no. of IDPN therapy holds had an inverse relationship with Alb improvement. The no. of IDPN therapy holds did not correlate with reported side effects, p value 0.08, thus we assume the therapy holds were unrelated to IDPN.
Conclusion
Patients with lower baseline Alb who receive therapy more consistently appear to have a greater response. Patients who are high responders appear to require an average of 4.3 months of treatment. There were no safety concerns observed with IDPN. More research on other health indicators as well as longitudinal post-IDPN clinical outcomes is needed to understand the full impact of the benefits of IDPN therapy in the ICHD population.
Funding
- Commercial Support – Baxter Healthcare Corporation, Clinical Nutrition Division; Patient Care America